KR101007497B1 - 베타 아미노기를 포함하는 ddp-ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물 - Google Patents
베타 아미노기를 포함하는 ddp-ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물 Download PDFInfo
- Publication number
- KR101007497B1 KR101007497B1 KR1020080036052A KR20080036052A KR101007497B1 KR 101007497 B1 KR101007497 B1 KR 101007497B1 KR 1020080036052 A KR1020080036052 A KR 1020080036052A KR 20080036052 A KR20080036052 A KR 20080036052A KR 101007497 B1 KR101007497 B1 KR 101007497B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- trifluorophenyl
- butanoyl
- piperazin
- formula
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
따라서, 본 발명은 하기 화학식 4의 화합물을 또한 제공한다:
[화학식 4]
상기 화학식 4에서, X는 상기 화학식1에서 정의된 바와 같으며, tert-부톡시, 메톡시, 에톡시, 이소프로폭시, 시클로펜틸옥시, 디에틸아미노, 에틸메틸아미노, 몰폴리노, tert-부틸티오 중에 선택된 1종인 것이 바람직하며, tert-부톡시인 것이 보다 바람직하다.
예 | IC50 (nM) |
MK-0431 | 28.3 |
실시예 1 | 0.72 |
실시예 2 | 7.4 |
실시예 3 | 2.2 |
실시예 4 | 4.3 |
실시예 5 | 1.7 |
실시예 6 | 11.0 |
실시예 7 | 17.4 |
실시예 8 | 5.2 |
실시예 9 | 1.3 |
실시예 10 | 48.7 |
실시예 11 | 0.8 |
실시예 12 | 1.05 |
실시예 13 | 0.81 |
실시예 14 | 0.92 |
실시예 15 | 0.87 |
실시예 16 | 0.73 |
실시예 17 | 1.2 |
실시예 18 | 0.71 |
예 | 실시예 1 | 실시예 3 | 실시예 12 | MK-0431 |
T1/2 (hour) | 7.9 | 7.6 | 5.5 | 4.8 |
Claims (9)
- 제1항에 있어서, 화학식 1의 화합물은 하기 화합물들로 이루어지는 군으로부터 선택되는 화합물;1) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(메톡시메틸)피페라진-2-온 염산염;2) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(에톡시메틸)피페라진-2-온 염산염;3) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(이소프로폭시메틸)피페라진-2-온 염산염;4) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부톡시메틸)피페라진-2-온 염산염;5) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(시클로펜 틸옥시메틸)피페라진-2-온 염산염;6) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-[(디에틸아미노)메틸]피페라진-2-온 이염산염;7) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-[(에틸메틸아미노)메틸]피페라진-2-온 이염산염;8) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(몰포리노메틸)피페라진-2-온 이염산염;9) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부틸티오메틸)피페라진-2-온 염산염;10) (S)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부톡시메틸)피페라진-2-온 염산염;11) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐) 부타노일]-3-(t-부톡시메틸)피페라진-2-온;12) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 타르타르산염;13) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 시트르산염;14) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 인산염;15) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시 메틸)피페라진-2-온 아세트산염;16) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 말산염;17) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 숙신산염 및18) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 아디프산염.
- 1) 화학식 3의 베타아미노기를 갖는 화합물과 화학식 4의 치환된 헤테로사이클 화합물을 1-하이드록시벤조트리아졸(HOBT), 1-에틸-3-(3-디메틸아미노프로필)카르보디이미드(EDC), 3차아민과 반응시켜 펩티드 결합으로 연결된 화학식 5의 화합물을 제조하는 단계 및 2) 상기 화학식 5의 화합물을 산 조건하에서 반응시키는 단계를 포함하는 화학식 2 화합물의 제조방법;상기 화학식 2, 4 및 5에 있어서, X는 OR1, SR1 또는 NR1R2이며, R1, R2는 각각 C1~C5의 저급알킬이고, NR1R2의 경우 R1과 R2는 O 의 헤테로 원소를 포함하여 5원 내지 7원의 고리를 이룰 수 있다.
- 제1항의 화학식 1로 표시되는 화합물, 이의 입체이성질체, 이의 약학적으로 허용되는 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물.
- 제5항에 있어서, 화학식 1의 화합물은 하기 화합물들로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물:1) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부톡시메틸)피페라진-2-온 염산염;2) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(에톡시메틸)피페라진-2-온 염산염;3) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(이소프로폭시메틸)피페라진-2-온 염산염;4) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(메톡시메틸)피페라진-2-온 염산염;5) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(시클로펜틸옥시메틸)피페라진-2-온 염산염;6) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-[(디에틸아미노)메틸]피페라진-2-온 이염산염;7) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-[(에틸메틸아미노)메틸]피페라진-2-온 이염산염;8) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(몰폴리노메틸)피페라진-2-온 이염산염;9) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부틸티오메틸)피페라진-2-온 염산염;10) (S)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)-부타노일]-3-(t-부톡시메틸)피페라진-2-온 염산염;11) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐) 부타노일]-3-(t-부톡시메틸)피페라진-2-온;12) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 타르타르산염;13) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 시트르산염;14) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 인산염;15) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 아세트산염;16) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 말산염;17) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 숙신산염 및18) (R)-4-[(R)-3-아미노-4-(2,4,5-트리플루오로페닐)부타노일]-3-(t-부톡시메틸)피페라진-2-온 아디프산염.
- 제7항에 있어서, 화학식 4의 X가 tert-부톡시, 메톡시, 에톡시, 이소프로폭시, 시클로펜틸옥시, 디에틸아미노, 에틸메틸아미노, 몰폴리노, tert-부틸티오 중에 선택된 1종인 화학식4의 화합물.
- 제7항에 있어서, 화학식 4의 X가 tert-부톡시인 화학식4의 화합물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070038462 | 2007-04-19 | ||
KR20070038462 | 2007-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080094604A KR20080094604A (ko) | 2008-10-23 |
KR101007497B1 true KR101007497B1 (ko) | 2011-01-12 |
Family
ID=39875638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080036052A KR101007497B1 (ko) | 2007-04-19 | 2008-04-18 | 베타 아미노기를 포함하는 ddp-ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8030315B2 (ko) |
EP (1) | EP2142519B1 (ko) |
JP (1) | JP5148686B2 (ko) |
KR (1) | KR101007497B1 (ko) |
CN (2) | CN101663282B (ko) |
AU (1) | AU2008241692B2 (ko) |
BR (1) | BRPI0810246B1 (ko) |
CA (1) | CA2683696C (ko) |
ES (1) | ES2526338T3 (ko) |
HK (2) | HK1138272A1 (ko) |
IL (1) | IL201524A (ko) |
MX (1) | MX2009011276A (ko) |
NZ (1) | NZ580701A (ko) |
PT (1) | PT2142519E (ko) |
RU (1) | RU2419615C1 (ko) |
WO (1) | WO2008130151A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220165346A (ko) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | 에보글립틴의 안정성이 개선된 제제 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101054911B1 (ko) * | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
KR101152898B1 (ko) * | 2009-03-30 | 2012-06-05 | 동아제약주식회사 | 디펩티딜 펩티다아제-ⅳ 저해제 및 중간체의 개량된 제조방법 |
US20120016125A1 (en) * | 2009-03-30 | 2012-01-19 | Dong-A Pharmaceutical. Co., Ltd | Method for preparing dipeptidyl peptidase-iv inhibitor and intermediate |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
SG183817A1 (en) * | 2010-03-24 | 2012-10-30 | Dong A Pharm Co Ltd | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
KR101180174B1 (ko) | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
KR101290029B1 (ko) | 2011-01-20 | 2013-07-30 | 에스티팜 주식회사 | 시타글립틴의 중간체 제조방법 |
CN102321014A (zh) * | 2011-05-27 | 2012-01-18 | 沈阳亿灵医药科技有限公司 | 新型双苯基吡啶类衍生物 |
US20140336196A1 (en) * | 2011-05-27 | 2014-11-13 | Merck Sharp & Dohme Corp. | Phosphoric acid salts of sitagliptin |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
BR112015032410B8 (pt) * | 2013-06-26 | 2021-10-26 | Dong A St Co Ltd | Uso de uma composição farmacêutica compreendendo inibidores de dpp-iv no preparo de um medicamento para prevenção ou tratamento de doenças renais |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
KR101709127B1 (ko) * | 2015-06-16 | 2017-02-22 | 경동제약 주식회사 | Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법 |
CN107382757A (zh) * | 2017-08-11 | 2017-11-24 | 苏州信恩医药科技有限公司 | 不对称烯丙基取代反应在依格列汀中间体合成中的应用 |
CN107417554A (zh) * | 2017-08-15 | 2017-12-01 | 苏州信恩医药科技有限公司 | 一种依格列汀中间体的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002088070A (ja) * | 2000-09-18 | 2002-03-27 | Mitsubishi Rayon Co Ltd | 新規ピペラジノン誘導体およびその製造方法 |
CA2499586A1 (en) * | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
PT1556362E (pt) | 2002-10-18 | 2008-06-16 | Merck & Co Inc | Compostos beta-amino heterocíclicos inibidores da dipeptidil peptidase para o tratamento ou prevenção da diabetes |
CA2533893A1 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
EP1541143A1 (en) * | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
JP4704914B2 (ja) * | 2003-12-11 | 2011-06-22 | 田辺三菱製薬株式会社 | α−アミノ酸誘導体及びその医薬用途 |
EP1593671A1 (en) * | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
EP1604989A1 (en) * | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
GB0413389D0 (en) * | 2004-06-16 | 2004-07-21 | Astrazeneca Ab | Chemical compounds |
WO2006104997A2 (en) | 2005-03-29 | 2006-10-05 | Merck & Co., Inc. | Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor |
JP2008031064A (ja) * | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
-
2008
- 2008-04-18 AU AU2008241692A patent/AU2008241692B2/en active Active
- 2008-04-18 CN CN2008800126267A patent/CN101663282B/zh active Active
- 2008-04-18 CN CN201110329468.1A patent/CN102516184B/zh active Active
- 2008-04-18 ES ES08741448.8T patent/ES2526338T3/es active Active
- 2008-04-18 CA CA2683696A patent/CA2683696C/en active Active
- 2008-04-18 JP JP2010503979A patent/JP5148686B2/ja active Active
- 2008-04-18 MX MX2009011276A patent/MX2009011276A/es active IP Right Grant
- 2008-04-18 US US12/596,281 patent/US8030315B2/en active Active
- 2008-04-18 EP EP08741448.8A patent/EP2142519B1/en active Active
- 2008-04-18 KR KR1020080036052A patent/KR101007497B1/ko active Protection Beyond IP Right Term
- 2008-04-18 NZ NZ580701A patent/NZ580701A/en unknown
- 2008-04-18 PT PT87414488T patent/PT2142519E/pt unknown
- 2008-04-18 WO PCT/KR2008/002203 patent/WO2008130151A1/en active Application Filing
- 2008-04-18 RU RU2009142602/04A patent/RU2419615C1/ru active
- 2008-04-18 BR BRPI0810246-5A patent/BRPI0810246B1/pt active IP Right Grant
-
2009
- 2009-10-14 IL IL201524A patent/IL201524A/en not_active IP Right Cessation
-
2010
- 2010-04-29 HK HK10104230.0A patent/HK1138272A1/xx unknown
-
2012
- 2012-12-13 HK HK12112891.1A patent/HK1172613A1/xx unknown
Non-Patent Citations (1)
Title |
---|
논문3; Tetrahedron Letters |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220165346A (ko) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | 에보글립틴의 안정성이 개선된 제제 |
Also Published As
Publication number | Publication date |
---|---|
WO2008130151A1 (en) | 2008-10-30 |
CN102516184A (zh) | 2012-06-27 |
AU2008241692B2 (en) | 2011-02-10 |
HK1172613A1 (en) | 2013-04-26 |
EP2142519A1 (en) | 2010-01-13 |
KR20080094604A (ko) | 2008-10-23 |
CA2683696C (en) | 2012-05-22 |
CN102516184B (zh) | 2015-03-25 |
US8030315B2 (en) | 2011-10-04 |
JP5148686B2 (ja) | 2013-02-20 |
PT2142519E (pt) | 2014-12-11 |
CA2683696A1 (en) | 2008-10-30 |
IL201524A (en) | 2014-09-30 |
CN101663282A (zh) | 2010-03-03 |
HK1138272A1 (en) | 2010-08-20 |
IL201524A0 (en) | 2010-05-31 |
ES2526338T3 (es) | 2015-01-09 |
MX2009011276A (es) | 2010-01-15 |
AU2008241692A1 (en) | 2008-10-30 |
RU2419615C1 (ru) | 2011-05-27 |
CN101663282B (zh) | 2012-02-15 |
BRPI0810246A2 (pt) | 2015-08-18 |
NZ580701A (en) | 2011-07-29 |
EP2142519B1 (en) | 2014-09-24 |
JP2011500508A (ja) | 2011-01-06 |
US20100120790A1 (en) | 2010-05-13 |
EP2142519A4 (en) | 2011-07-13 |
BRPI0810246B1 (pt) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101007497B1 (ko) | 베타 아미노기를 포함하는 ddp-ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물 | |
JP5424256B2 (ja) | アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼivの阻害剤としての用途 | |
US7125863B2 (en) | Inhibitors of dipeptidyl peptidase IV | |
EP1680418B1 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
JP2002363157A (ja) | 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物 | |
US9453014B2 (en) | Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof | |
TW200938530A (en) | Pyrrolidine compounds | |
JP2009190971A (ja) | 2−シアノピロリジン誘導体 | |
JP2010533672A (ja) | 新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用 | |
CA2743558C (fr) | Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique | |
US20220017496A1 (en) | Disubstituted pyrazole compounds | |
RU2499792C2 (ru) | Усовершенствованный способ получения ингибитора дипептидилпептидазы-iv и промежуточного соединения | |
RU2498976C2 (ru) | Усовершенствованный способ получения ингибитора дипептидилпептидазы-iv и промежуточного соединения | |
US10807971B2 (en) | Pyrrolidinone compounds | |
EP2401268A1 (en) | Oxyindole derivatives with motilin receptor agonistic activity | |
KR20070054807A (ko) | Dpp-ⅳ 저해 활성을 갖는 베타 아미노기를 포함하는헤테로사이클 화합물, 이의 제조방법, 및 이를유효성분으로 함유하는 약학적 조성물 | |
EP2185525B1 (fr) | Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique | |
Peng et al. | A Cost-Effective Method to Prepare Pure Vildagliptin | |
KR20080007764A (ko) | 베타아미노기를 갖는 1,2,5-트리아제판 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 | |
EP1918284A1 (en) | Hydrazinopyrimidines as cysteine protease inhibitors | |
US20080096897A1 (en) | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | |
JP2009137864A (ja) | 医薬組成物 | |
CN104003992A (zh) | 一种抑制dpp-iv的化合物及其中间体 | |
EP2030621A1 (en) | Novel substituted pyrimidines as cysteine protease inhibitors | |
KR20060086404A (ko) | 아졸리딘카르보니트릴 및 dpp-ⅳ 억제제로서의 이의용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141211 Year of fee payment: 5 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161222 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |